Litcius/Paper detail

Validation of a commercially available SARS-CoV-2 serological immunoassay

Benjamin Meyer, Giulia Torriani, Sabine Yerly, Léna Mazza, Antoanella Calame, Isabelle Arm‐Vernez, Gert Zimmer, Thomas Agoritsas, Jérôme Stirnemann, Hervé Spechbach, I Guessous, Silvia Stringhini, Jérôme Pugin, P Roux‐Lombard, Lionel Fontao, Claire‐Anne Siegrist, Isabella Eckerle, Nicolas Vuilleumier, Laurent Kaiser

2020Clinical Microbiology and Infection174 citationsDOIOpen Access PDF

Topics & Concepts

ImmunoassaySerologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)Virology2019-20 coronavirus outbreakMedicineBetacoronavirusAntibodyImmunologyInfectious disease (medical specialty)PathologyOutbreakDiseaseSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingvaccines and immunoinformatics approaches
Validation of a commercially available SARS-CoV-2 serological immunoassay | Litcius